Personalized siRNA-Based Nanomedicines for the Treatment of Cancer

The ability to silence specific genes using small interfering RNA (siRNA) delivered by lipid nanoparticle (LNP) systems in vivo offers interesting possibilities for the rapid design of personalized therapeutics to treat cancer. In particular, identification of causal genes from whole genome sequencing of a patient's tumor potentially allows the rapid generation of individualized LNP siRNA systems to silence those genes and inhibit tumor growth. Progress towards this objective will be presented.